256 related articles for article (PubMed ID: 33594045)
21. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
[TBL] [Abstract][Full Text] [Related]
22. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
[TBL] [Abstract][Full Text] [Related]
23. Pilot Study of Bortezomib and Dexamethasone Pre- and Post-Risk-Adapted Autologous Stem Cell Transplantation in AL Amyloidosis.
Landau H; Lahoud O; Devlin S; Lendvai N; Chung DJ; Dogan A; Landgren CO; Giralt S; Hassoun H
Biol Blood Marrow Transplant; 2020 Jan; 26(1):204-208. PubMed ID: 31446197
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal Flow Cytometry Identified "Minimal Residual Disease" (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma.
Gu J; Liu J; Chen M; Huang B; Li J
Biol Blood Marrow Transplant; 2018 Dec; 24(12):2568-2574. PubMed ID: 30142420
[TBL] [Abstract][Full Text] [Related]
25. Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis.
Li H; Li F; Zhou X; Mei J; Song P; An Z; Zhao Q; Guo X; Wang X; Zhai Y
Ann Hematol; 2019 May; 98(5):1185-1195. PubMed ID: 30721336
[TBL] [Abstract][Full Text] [Related]
26. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Paiva B; Puig N; Cedena MT; Rosiñol L; Cordón L; Vidriales MB; Burgos L; Flores-Montero J; Sanoja-Flores L; Lopez-Anglada L; Maldonado R; de la Cruz J; Gutierrez NC; Calasanz MJ; Martin-Ramos ML; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Blanchard MJ; Rios R; Martin J; Martinez-Martinez R; Sureda A; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Van Dongen JJM; Orfao A; Mateos MV; Blade J; San-Miguel JF; Lahuerta JJ;
J Clin Oncol; 2020 Mar; 38(8):784-792. PubMed ID: 31770060
[TBL] [Abstract][Full Text] [Related]
27. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
28. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
29. Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis.
Muchtar E; Dispenzieri A; Jevremovic D; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Warsame R; Kourelis TV; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Kumar SK; Gertz MA
Amyloid; 2020 Mar; 27(1):13-16. PubMed ID: 31544536
[TBL] [Abstract][Full Text] [Related]
30. Flow cytometry remission by Ig light chains ratio is a powerful marker of outcome in multiple myeloma after tandem autologous transplant: a real-life study.
Cordone I; Marchesi F; Masi S; Summa V; Pisani F; Merola R; Cigliana G; Orlandi G; Gumenyuk S; Palombi F; Romano A; Spadea A; Renzi D; Papa E; Canfora M; Conti L; Petti MC; Mengarelli A
J Exp Clin Cancer Res; 2016 Mar; 35():49. PubMed ID: 26992692
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of minimal residual disease in multiple myeloma patients detected by 8-color panels and next generation flow cytometry].
Wang XF; Wang TT; Zhang ZY; Zhou HX; Zhang YR; Chen WM; Geng CY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):512-517. PubMed ID: 31340626
[No Abstract] [Full Text] [Related]
32. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
[TBL] [Abstract][Full Text] [Related]
33. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277
[TBL] [Abstract][Full Text] [Related]
34. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
[TBL] [Abstract][Full Text] [Related]
35. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Goicoechea I; Puig N; Cedena MT; Burgos L; Cordón L; Vidriales MB; Flores-Montero J; Gutierrez NC; Calasanz MJ; Ramos MM; Lara-Astiaso D; Vilas-Zornoza A; Alignani D; Rodriguez I; Sarvide S; Alameda D; Garcés JJ; Rodriguez S; Fresquet V; Celay J; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Rios R; Martin-Sanchez J; Martinez-Martinez R; Sarra J; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Martinez-Climent JA; Orfao A; Rosiñol L; Mateos MV; Lahuerta JJ; Blade J; San Miguel J; Paiva B
Blood; 2021 Jan; 137(1):49-60. PubMed ID: 32693406
[TBL] [Abstract][Full Text] [Related]
36. [Predictable recurrence by regular monitoring minimal residual disease with flow cytometry in the patients with both AML and ALL: a single-center study of 163 cases].
Tong CR; Wang H; Yang JF; Lin YH; Zhang X; Zhao J; Fei XH; Gu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):748-51. PubMed ID: 22339910
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?
Lee H; Duggan P; Neri P; Tay J; Bahlis NJ; Jimenez-Zepeda VH
Bone Marrow Transplant; 2017 Jun; 52(6):915-917. PubMed ID: 28287637
[No Abstract] [Full Text] [Related]
38. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease negativity by next-generation flow in non-CR myeloma patients.
Kim SM; Yang NE; Jeong D; Yun J; Ryu S; Yoon SS; Ahn YO; Lee DS
EJHaem; 2020 Nov; 1(2):563-566. PubMed ID: 35844993
[TBL] [Abstract][Full Text] [Related]
40. Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan.
Takamatsu H
Int J Hematol; 2020 Apr; 111(4):519-529. PubMed ID: 32034671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]